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Abstract 
Acrylic bone cements have an elastic modulus several times higher than the 
surrounding trabecular bone. This has been hypothesized to contribute to certain 
clinical complications. There are indications that the addition of specific fatty acids 
and triglyceride oils may reduce the elastic modulus of these types of cements. Some 
of these additives also appear to have inherent antibiotic properties, although this has 
never been evaluated in bone cements. In this study, several types of fatty acids and 
triglyceride oils were evaluated for use in acrylic bone cements. Their mechanical 
properties were evaluated under uniaxial compression testing and selected cements 
were then further characterized in terms of microstructure, handling and antibacterial 
properties using scanning electron microscopy, polymerization temperature 
measurements, agar diffusion tests and bactericidal activity assays of cement extracts. 
It was found that any of the evaluated fatty acids or triglyceride oils could be used to 
tailor the stiffness of acrylic bone cements, although at varying concentrations, which 
also depended on the type of commercial base cement used. In particular, the addition 
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of very small amounts of linoleic acid (<2.0 wt%) resulted in Young’s moduli and 
compressive strengths in the range of human trabecular bone, while maintaining a 
similar setting time. Further, the addition of 12.6 wt% ricinoleic acid to Osteopal V 
cement was found to have a significant antibacterial effect, inhibiting growth of 
Staphylococcus aureus in an agar diffusion test as well as demonstrating 100% 
bactericidal activity against the same strain.  
 
Keywords: PMMA, bone cement, low-modulus, mechanical, antibacterial, fatty acid, 
triglyceride oil
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1. Introduction 
 
Acrylic bone cements, mainly based on poly(methyl methacrylate) (PMMA), have 
been used in orthopedics since the 1960’s for joint prosthesis fixation and since the 
1980’s for vertebroplasty, and are still extensively used. 1-3 These cements are readily 
available as a system consisting of a liquid and a powder to be mixed and applied in a 
liquid form as an injectable material or in a more viscous form as a paste. They can 
also be used in their set state as e.g. beads or spacers for local treatment of infection. 4 
A basic formulation consists of a) a powder, which is composed of prepolymerized 
polymer beads mixed with a radical initiator, typically benzoyl peroxide, and a 
radiopacifier, typically barium sulphate or zirconium dioxide; and b) a liquid, which 
is composed of acrylic monomer, and a peroxide decomposer, typically N,N-
dimethyl-p-toluidine. Some formulations contain other additives such as dyes, 5 used 
to differentiate the cement from the bone in the case of open surgery or explantation; 
bioactive fillers, 6 used with the aim of enhancing bone integration; additional 
radiopacifier, for enhanced visibility in minimally invasive applications, 7, 8 and 
antibiotics, to prevent or treat infection. 4, 7 Although these additives are available in 
commercial formulations, cements are some times modified directly in the operating 
theater with some of these additives, e.g. through the addition of extra radiopacifier to 
cements intended for prosthesis fixation, 7, 8 or through the addition of antibiotics. 4, 7 
Besides the above modifications, experimental formulations containing e.g. 
plasticizers have been investigated in order to reduce the stiffness of the cements. 9 
This is because the excessive stiffness of acrylic bone cements in comparison to the 
surrounding trabecular bone may contribute to biomechanically related complications, 
mainly noted after vertebroplasty. 10-13 In fact, most commercial acrylic bone cements 
have an elastic modulus in the range of 1700-3700 MPa, 14, 15 while the elastic 
modulus of vertebral trabecular bone is typically in the ranges of 10-750 MPa, 16-18 
encompassing osteoporotic to healthy bone.	   New fractures occurring after 
vertebroplasty may partly be due to the underlying disease, but some studies have 
reported a larger amount of new fractures next to the vertebrae treated with PMMA. 
19-21 The maximum filling approach, in which as much cement as possible is injected 
into the vertebra, has been suggested to have a particularly detrimental effect. 22, 23. 
However, the stiffness and strength of vertebrae have been found to be only weakly 
correlated with the volume fill 24-26, suggesting that even relatively small amounts of 
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high-stiffness PMMA cements may induce a large increase in stiffness. Several 
experimental studies have therefore focused on developing novel PMMA-based 
cements with a lower elastic modulus by using additives such as hydrogels 27, 28 or 
lactam plasticizers. 29 Even though these attempts have proved successful in terms of 
tailoring the mechanical properties of the cements, none of these cements are 
commercially available. One reason for this could be that an excessive particle release 
has been found when aqueous phases are used in PMMA to obtain a reduced 
modulus30. 
Unsaturated fatty acids, which esterified to glycerol form triglycerides, are natural 
compounds that have recently been given more attention in chemical processes 
because of their potential for chemical modifications due to unsaturations and 
carboxyl groups in their structure. 31 Different approaches to incorporate compounds 
from this family into bone cements have been attempted. For instance, Vázquez et al. 
32 used aromatic amines as well as acrylic monomers, both derived from oleic acid, as 
components to improve bone cements. The authors reported similar compressive 
strength and a reduction of 62% in the Young’s modulus when a modified liquid 
phase containing 2.57 wt% 4-N,N-dimethylaminobenzyl oleate was used. 32 Lam et 
al. 33 modified bone cements with strontium-substituted hydroxyapatite-nanoparticles 
and linoleic acid, and reported a reduction of 15% in compressive strength and 57% in 
the Young’s modulus when 15 vol% linoleic acid was incorporated into the liquid 
phase. 33 In previous work, we added castor oil to commercially available PMMA and 
found that 12 wt% castor oil decreased the strength and the Young’s modulus by 83% 
and 70%, 34 respectively. However, the castor oil appeared to interfere with the setting 
reaction, reducing the cell viability in a worst-case scenario. 34 Although further, 
preliminary testing has suggested that a modification of the monomer-to-additive ratio 
could improve biocompatibility, the possibility of using another type of fatty acid or 
derivative thereof, which requires lower concentrations, remains an interesting 
opportunity. However, there is no systematic study available comparing different 
types of modifiers in PMMA bone cement. One aim of this study was therefore to 
screen different compounds in the fatty acid/triglyceride oil family to select the most 
suitable additive to control the mechanical properties of commercial bone cements for 
vertebroplasty. Furthermore, since these compounds could remain unreacted and 
provide an increase in intermolecular free volume, there may be an additional positive 
effect in terms of the drug release of the cement. PMMA cements alone have a limited 
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drug delivery capacity, with the main delivery stemming from the surface of the 
cement, which means an excessive amount of drug has to be incorporated into the 
cement. A large quantity of the drug remains inside the cement and slowly leaks out, 
possibly causing increased bacterial resistance in the case of antibiotics. 35 Unreacted 
additive molecules may provide additional paths for drug release and hence an 
enhanced drug delivery from the PMMA cement, requiring less antibiotic addition. 
Furthermore, some of the compounds of interest have demonstrated inherent 
antibiotic properties and could therefore enhance the effect of an incorporated 
antibiotic. 36, 37 However, to the authors’ knowledge, no report is available on the 
antibacterial effect of combining a fatty acid with an antibiotic. A second aim of this 
study was hence to evaluate the antibacterial properties of modified cements, with and 
without antibiotics. To meet the aims of the study, various commonly found fatty 
acids and triglyceride oils, namely, ricinoleic acid, methyl linoleate, linoleic acid, 
tung oil, linseed oil, and castor oil were incorporated into two types of commercial 
bone cements for screening. The mechanical properties were evaluated under uniaxial 
compression and selected cements were then further characterized in terms of 
microstructure, handling, antibacterial properties and monomer release using scanning 
electron microscopy (SEM), polymerization temperature measurements, agar 
diffusion tests and bactericidal activity assays as well as monomer content of cement 
extracts. 
 
2. Materials and methods 
2.1 Material preparation 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless 
otherwise specified. A cement intended for vertebroplasty, Osteopal V (OP; Heraeus 
Medical GmbH, Hanau, Germany) was used as one base cement. Osteopal V has a 
liquid to powder ratio of 0.385 ml/g and the powder phase contains 54.6 wt% 
poly(methyl acrylate-co-methyl methacrylate), 45.0 wt% zirconium dioxide, 0.4 wt% 
benzoyl peroxide, and chlorophyll VIII. The monomer phase contains 92 wt% methyl 
methacrylate, 2 wt% N,N-dimethyl-p-toluidine and 6 wt% other additives including 
chlorophyll VIII and hydroquinone. A cement for prosthesis fixation, Simplex P (SP; 
Stryker Corporation, Kalamazoo, MI, USA) was also used as base cement, however 
for mechanical testing only, to confirm the concept for these types of cements. 
Simplex P has a liquid to powder ratio of 0.5 ml/g and the powder phase contains 73.7 
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wt% poly(methyl methacrylate-co-styrene), 15 wt% poly(methyl methacrylate), 10 
wt% barium sulphate, 1.7 wt% benzoyl peroxide. The monomer phase contains 97.5 
wt% methyl methacrylate and 2.5 wt% N,N-dimethyl-p-toluidine. The following 
compounds in the fatty acid/triglyceride oil family were tested as additives: linoleic 
acid (LA; ≥99%), ricinoleic acid (RA; ∼ 80%), methyl linoleate (ML; ≥99%), tung oil 
(TO), linseed oil (LO), and castor oil (CO). Modified cements were prepared by first 
removing 54% of the additive volume from the monomer phase. The additive was 
then added to the monomer and the modified monomer phase was homogenized using 
a Vortex-Genie 2 mixer (Scientific Industries, Bohemia, NY, USA) prior to cement 
preparation. The bone cements were prepared by adding the monomer phase to the 
powder phase inside 50 mL Falcon tubes, and then mixed for 30 seconds using a cap-
vibrator (Ivoclar Vivadent AB, Solna, Sweden). 
 
2.2 Mechanical testing 
Specimens of ∅=6 mm and h=12 mm were tested after 24 h setting in air at room 
temperature. 38 Uniaxial compression tests were performed under displacement 
control at 6 mm/min using an AGS-X materials testing machine (Shimadzu, Kyoto, 
Japan). The Young’s modulus (E) and compressive strength (σc) (yield stress at 2% 
offset or upper yield point, whichever occurred first 38) were determined from the 
stress-strain data. Since different additives affected the properties to different extent, 
various concentrations were tested until cements with a combination of a Young’s 
modulus below 750 MPa and a strength above 10MPa were obtained, since such 
Young’s modulus is in the upper range of elastic moduli of vertebral trabecular bone, 
16, 18 and the strength corresponds to the highest values reported for vertebral 
trabecular bone 17 (although mixed with femoral specimens – other highest values 
reported for vertebral trabecular bone lie at approx. 5MPa 18). Based on the results, a 
few compositions were selected for further characterization, as further detailed in 
section 3.1. 
 
2.3 Microstructure 
The microstructure of the cements was examined by scanning electron microscopy 
(SEM). The images were acquired on a LEO 1550 scanning electron microscope (Carl 
Zeiss AG, Oberkochen, Germany) operated at an acceleration voltage of 2.00 kV, 
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with a secondary electron detector for topographic contrast, and at a working distance 
of 10 mm. Prior to SEM imaging, the samples were polished down to 1200 grit and 
sputter-coated with palladium.	  The samples were prepared 24 h prior to polishing and 
then stored under vacuum overnight prior to coating. 
 
2.4 Handling properties 
The maximum polymerization temperature (Tmax) and the setting time (tsetting), defined 
as the time taken to reach a temperature midway between ambient and maximum 
temperature, were determined according to the standard procedure described in ISO 
5833, with four replicates per group. 38 The glass transition temperature of the 
cements was assessed through differential scanning calorimetry using a DSC Q1000 
(TA Instruments, United States). A heat/cool/heat ramp experiment was performed 
using a heating rate of 10°C/min up to 200°C and a cooling rate of 20°C/min, down to 
-80°C. The glass transition temperature was determined from the second heat ramp.  
 
2.5 Antimicrobial properties 
Vancomycin was added to selected cements in order to evaluate the antibacterial 
properties of the modified cements as well as the effect of combining a fatty acid or 
its derivative with an antibiotic. Vancomycin was chosen as it is commonly used in 
PMMA bone cement for revision arthroplasty. 39, 40 
The antibacterial activity of the samples was tested using the gram-positive bacterium 
Staphylococcus aureus (Culture Collection, University of Göterborg, Sweden). 
S.aureus was grown and maintained in Brain Heart Infusion (BHI) broth (Scharlau, 
Spain). The culture was incubated overnight at 37ºC before each assay and the assays 
were performed in static conditions due to the short testing time. 
Agar diffusion test: The relative antibacterial activity of selected formulations with 
and without antibiotic (2.4 wt% of powder 39) was determined through an agar 
diffusion test. The test was performed by spreading 200 µL of bacterial suspension 
(1·108 colony forming units (CFU)/mL, O.D. of 0.2 ± 0.01 at 600 nm) homogenously 
on every BHI agar plate, previously prepared with the appropriate culture media 
containing 1.5% bacteriological agar (Scharlau, Spain). Disc-shaped specimens (∅=7 
mm; h=3.5 mm) of cements were prepared and four equidistant cavities of the same 
size were punched in the agar and the specimens placed inside, after 1 h of setting in 
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air at room temperature. Images of the specimens were taken with a digital camera 
after incubation for 24 hours at 37°C. The inhibition zone size was calculated as the 
mean difference between the inhibition zone diameter and the cement-filled cavity 
diameter. Six replicates were performed per formulation.  
Bactericidal assay: The antimicrobial activity of cement extracts was assessed using 
disc-shaped specimens (∅=7.5 mm; h=2 mm) of cements. Extracts were prepared by 
soaking the cements, after 1 h of setting in air at room temperature, in phosphate 
buffered saline (PBS) solution according to the ISO 10993 standard at a surface-to-
PBS medium of 3 cm2/mL for 24 hours at 37°C. 41 Staphylococcus aureus (2×105 
CFU/mL) was incubated in the cement extracts for 2 hours at 37°C. 100 µL aliquots 
from these extracts were subsequently spread on agar plates, and the number of 
surviving colonies counted after incubation for 24 hours at 37°C. The percentage of 
surviving colonies was calculated with respect to the surviving colonies in the 
positive control (PBS only). Four replicates per formulation were performed. 
 
2.6 Monomer release 
Extracts were prepared after 1 h of setting in air at room temperature, using six 
specimens (∅=7.7mm, h=3.5mm) per group. Extractions were done for each group by 
submerging all 6 specimens in 3.55 mL PBS for 24 h at 37°C, similarly to the 
antibacterial tests. Afterwards, 2 mL aliquots from each solution were introduced in a 
head space vial and closed hermetically. The vials were incubated at 80°C during 30 
min. The analysis was performed by gas chromatography-mass spectrometry (HS-
GC/MS), by injecting 1 mL of the vapor phase through a special syringe kept at 85°C. 
A Trace GC Gas Chromatograph with Triplus head space injector coupled to a DSQII 
mass spectrometer (ThermoFisher Scientific, Waltham, MA) was used. A ZB-624 
column (60 m × 0.32 mm × 1.8 m) with a helium flow of 1.8 mL/min was used for 
separation. The oven temperature programme consisted of 2 min hold at 60°C, 
followed by 8°C/min ramp to 220°C and a 5 min hold at 220°C. The temperature of 
the injector, interface, and ionization source was set at 220, 260, and 200°C, 
respectively. 
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2.7 Statistical Analysis 
IBM SPSS Statistics v. 21 (IBM, Chicago, IL, USA) was used to perform analyses of 
variance (ANOVA) followed by Scheffe’s post-hoc test in order to evaluate statistical 
differences between groups. When homogeneity of variance could not be confirmed 
(using Levene’s test), Welch’s robust test of equality of means was used together with 
Tamhane’s post-hoc test. A significance level of α=0.05 was used. 
 
3. Results 
3.1 Mechanical properties 
The properties of the base (control) cements in which the additives were evaluated are 
summarized in Table 1. Table 2 shows the mechanical properties of Simplex P and 
Osteopal V modified with fatty acids: ricinoleic acid, linoleic acid methyl ester 
(methyl linoleate) and linoleic acid. Linoleic acid as well as its methyl ester had a 
more pronounced effect on the Young’s modulus of both Simplex P and Osteopal V 
compared to ricinoleic acid. Table 3 shows the mechanical properties of Simplex P 
and Osteopal V modified with triglyceride oils: linseed oil, tung oil and castor oil. 
Linseed oil and tung oil had a more pronounced effect on the Young’s modulus than 
castor oil. In general, lower amounts of additive were required to reach similar 
mechanical properties for Osteopal V than for Simplex P. 
Two fatty acids (linoleic acid and ricinoleic acid) and one triglyceride oil (castor oil) 
were selected for further testing with Osteopal V: more ricinoleic acid than lineoleic 
acid or methyl linoleate was needed for the same effect on the properties, while the 
effect of methyl linoleate was similar to that of linoleic acid; further, castor oil 
contains mainly ricinoleic acid but also linoleic acid and no methyl linoleate. 
Regression analysis was performed on the Young’s modulus and ultimate strength 
results of the cements containing the selected additives, and cements predicted to have 
a similar modulus and fulfilling the criteria of a Young’s modulus below 750MPa and 
a strength above 10 MPa were further characterized. These were Osteopal V cements 
containing 1.0 wt% linoleic acid, 12.6 wt% ricinoleic acid and 12.3 wt% castor oil, 
hereinafter referred to as OP-1.0%LA, OP-12.6%RA and OP-12.3%CO. Their 
mechanical properties, with and without antibiotic, were confirmed according to the 
same testing protocol as before (see section 2.2), and these results are shown in Table 
4. Cements containing Vancomycin are designated with VA, i.e. Osteopal V cement 
	   10	  
modified with 1.0 wt%LA and 2.4 wt% Vancomycin (of powder) is named OP-
1.0%LA-VA. OP and OP-VA had significantly higher elastic moduli and compressive 
strengths than the other cements (p<0.001). No other statistically significant 
differences were found, i.e. no statistically significant difference was found between 
OP and OP-VA (p=0.1), nor between OP-1.0%LA, OP-12.6%RA and OP-12.3%CO 
as well as their corresponding Vancomycin-containing formulations (p>0.05).  
 
3.2 Microstructure 
The surface microstructure of Osteopal V and its modified low-modulus formulations 
was assessed through scanning electron microscopy (Figure 1). Osteopal V modified 
with linoleic acid (Figure 1B) exhibited a similar microstructure to that of unmodified 
Osteopal V (Figure 1A), displaying a dense, highly polymerized material, with no 
major features. On the other hand, low-modulus Osteopal V modified with ricinoleic 
acid and castor oil (Figures 1C and D, respectively) exhibited a more irregular porous 
surface where the spherical polymer beads (20-90 µm) as well as the irregular 
zirconia particles (used as radiopacifier) were distinguishable. 
 
3.3 Handling properties 
The handling properties of the selected cements are shown in Table 5. The setting 
times of cements containing ricinoleic acid and castor oil were significantly lower 
than the control (p≤0.001), but there was no significant difference between the two 
(p>0.05). All low-modulus formulations gave significantly lower polymerization 
temperatures than the unmodified cement (p<0.001), but no difference was found 
between the modified cements (p>0.05).  
 
3.4 Antimicrobial properties 
The inhibitory zones resulting from the agar diffusion test are shown in Figure 2A. 
Unmodified Osteopal V showed virtually no inhibitory zone. A clear inhibitory effect 
was however observed for all the formulations when Vancomycin was added 
(p≤0.01). An inhibitory effect could also be seen for the formulations without 
antibiotic but containing other additives, although this effect was statistically 
significant for ricinoleic acid only (p<0.001, in comparison to unmodified Osteopal 
V).  
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The results for the bactericidal activity of the extracts are shown in Figure 2B as 
percentage of viable bacteria in comparison to PBS only. Unmodified Osteopal V was 
significantly different only to cements containing ricinoleic acid, with or without 
antibiotic (p=0.02), which both showed the highest bactericidal activity (no viable 
bacteria). No difference was found between groups with and without antibiotic, 
except for cements containing linoleic acid (p=0.01).  
 
3.5 Monomer release 
Chromatography-mass spectrometry (HS-GC/MS) gave a concentration of MMA in 
the extracts of 1.40, 2.13, 0.75 and 0.96 g/l for OP, OP-1.0%LA, OP-12.6%RA and 
OP-12.3%CO, respectively. 
 
4. Discussion 
In this study different fatty acids and triglyceride oils were tested as potential 
additives to acrylic bone cements with two purposes: A) to tailor the Young’s 
modulus towards values closer to those of human trabecular bone; B) to achieve 
enhanced antibacterial properties of the cements. To screen the applicability of these 
compounds in the clinical setting we chose two base cements, Osteopal V, intended 
for vertebroplasty, and Simplex P, intended for prosthesis fixation. The results for the 
mechanical properties clearly indicated that among the tested fatty acids, linoleic acid 
and its methyl ester had the largest effect on the final values since lower additive 
concentrations were required to achieve properties similar to human trabecular bone 
(Table 2). The reason for this could be the increased availability of the end hydrogen 
atom for abstraction in combination with the polyunsaturation of linoleic acid and its 
methyl ester in comparison to ricinoleic acid. The level of unsaturation of a fatty acid 
or a triglyceride is commonly measured in terms of the iodine value (the mass of 
iodine in grams that is consumed by 100g of a substance), which is 181.0 and 85.1 mg 
for linoleic and ricinoleic acid, respectively 31 indicating that a higher iodine value 
increases the reactivity of the fatty acid within the bone cement. Methacrylation of the 
polyunsaturated fatty acids can occur via chain transfer. 42 Previous studies on a 
similar type of reaction have suggested that the methyl methacrylate (MMA) radicals 
may graft by abstraction of the alpha-hydrogen in the fatty acid. 42 Thereby, fatty 
acids reduce the modulus of the cement through grafting and formation of stable 
radicals that slow down the polymerization and shorten the chains. 42 Also, the 
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presence of these large molecules increases the free volume and facilitates the relative 
movement of the polymer chains, thereby decreasing the glass transition temperature 
and lowering the elastic modulus of the material, as seen in Table 5. The results also 
indicated that among the tested triglyceride oils, linseed and tung oil had the largest 
effect on the final mechanical properties (Table 3). The major components of linseed, 
tung, and castor oil, are linolenic acid (55%), α-Eleostearic acid (82.0%), and 
ricinoleic acid (87.5%), respectively. 31 The iodine values for triglycerides from these 
fatty acids are 261.6 mg for linolenic and α-Eleostearic acid and 81.6 mg for 
ricinoleic acid. This indicates that, also for the triglyceride oils, the higher efficacy in 
decreasing the mechanical properties stems from the reactivity of the additive.  
Larger amounts of additives were generally required in Simplex P compared to 
Osteopal V to reach similar moduli. This followed from the relative amounts of 
cement components (see section 2.1): in order to reach a similar additive to monomer 
ratio, a larger weight percentage of the total cement was needed in Simplex P. 
Interestingly, a much lower vol% (approximately 3 vol% compared to 15 vol%) of 
linoleic acid was needed to achieve a similar reduction in modulus in the current 
study compared to the study by Lam et al. 43 However, in the study by Lam et al., the 
cements also contained 20 wt% (of powder) linoleic-acid functionalized strontium 
substituted hydroxyapatite particles, which hence appeared to limit the effect of the 
added linoleic acid, possibly due to the hypothesized formation of a copolymer on the 
particle-cement interface. 43 
The setting time decreased for the cements containing ricinoleic acid and castor oil 
compared to the control, while the cement containing linoleic acid gave no significant 
difference. The use of fatty acids or triglyceride oils also had a positive effect on the 
peak polymerization temperature, which was reduced by almost 30°C. A reduction in 
peak polymerization temperature could be beneficial from a clinical perspective, as 
high polymerization temperatures may have negative effects on surrounding tissues. 
44, 45 It can be noted, however, that the amounts used to measure the setting time and 
maximum temperature according to the standard38 are much larger than those used in 
e.g. vertebroplasty. The additives reduced the glass transition temperature of the 
modified cements, which could be due to shorter polymer chains besides increased 
interchain spacing as explained above. The decrease in setting time, polymerization 
temperature and glass transition temperature of cements containing ricinoleic acid and 
castor oil could also be related to the smaller amount of monomer that was available 
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to react in these formulations (see section 2.1). Since the activator was present in 
excess in the liquid phase, approximately the same number of reactions could be 
started by the initiator from the powder phase, giving a shorter setting time and 
shorter chains. In fact, the SEM images (Figure 1) indicated that the morphology of 
these cements was not homogeneous, being affected by the presence of a non-
polymerizing phase. Conversely, the cement containing linoleic acid appeared 
homogeneous and its setting time was not significantly affected.  
The agar diffusion test showed that the antibiotic Vancomycin was released from all 
the materials creating an inhibitory zone that prevented the growth of Staphylococcus 
aureus (Figure 2A). No significant improvement in inhibitory effect was detected as a 
result of any of the additives, despite the apparently more open structure of the 
ricinoleic acid and castor oil containing cements. However, the test confirmed that the 
materials containing fatty acids or a triglyceride oil had a certain inhibitory effect 
even without added antibiotic. 36, 37 Regarding the bactericidal activity of cement 
extracts (Figure 2B), a difference due to the addition of antibiotic was found for 
cements containing linoleic acid only, likely due to relatively large variances in some 
cases together with the limited number of specimens (3-4 per group). In fact, in a 
previous study, where a similar amount of Vancomycin in another commercial 
formulation (Cemex XL, Tecres) was used, 39 a bactericidal activity was found 
without other additives than the antibiotic. However, much larger cement disks were 
used (∅=15 mm; h=10 mm compared to our ∅=7.5 mm; h=2 mm), together with a 
lower seeding density (1⋅105 CFU/ml in comparison to our 2⋅105 CFU/ml). Similarly 
to the agar test, the additives used in the present study appeared to give a bactericidal 
effect of their own, but a significant difference to the control was detected only for 
cements containing ricinoleic acid, which showed 100% bactericidal activity, i.e. no 
viable bacteria was detected, regardless of the use of antibiotic. Although, to the best 
of the authors knowledge, there is no data available on the antibacterial effects of 
ricinoleic acid itself, some of its derivatives have been found to have antibacterial 
properties46. Residual monomer may have toxic effects47, however the monomer 
release study confirmed that the bactericidal effect of ricinoleic acid-containing 
cements was not likely to be due to an increase in monomer release from these 
cements. In fact, the ricinoleic acid- as well as the castor oil-containing cements gave 
a lower monomer release than the control, possibly due to the removal of monomer 
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from the original composition during preparation of these cements (see section 2.1) 
and the faster setting. Any possible negative biological effect of the ricinoleic acid-
containing cements however needs to be evaluated in a future study. The addition of 
linoleic acid, which entailed removal of much less monomer than for the other 
modified cements, gave a higher monomer release than the control, possibly due to 
the reduced polymerization rate, as discussed above. However, preliminary data 
indicates that although linoleic acid- and castor oil-containing cements give a lower 
cell viability for osteoblast-like Saos-2 cells in contact with undiluted extracts, 
dilutions of as little as 4-10 times give viabilities not significantly different to the 
control (data not shown). Future work should include in vivo evaluation of the 
cements’ biocompatibility as well as further studies elucidating the possible 
antibacterial effect of the ricinoleic acid. 
Further, it should be noted that, while in the current study a lower modulus was aimed 
for, the modifications also entailed a lower strength. A strength of above 10MPa was 
set as the limit, in line with literature values for vertebral trabecular bone 17, 18. 
However, while this may be adequate for the vertebroplasty application, the ISO 
standard for acrylic cements for prosthesis fixation cites a minimum strength of 
70MPa38. Hence, while the use of the additives could be useful for lowering the 
modulus of vertebroplastic cements, and/or achieving antibacterial properties without 
the need for an additional antibiotic, the use of these cements in other applications 
may be restricted to limited or non load-bearing situations, such as beads for the local 
treatment of infection 48. 
In summary, PMMA based cements with a lower elastic modulus as well as improved 
antibacterial properties were produced using fatty acids and triglyceride oils. Whereas 
low-modulus cements modified with small amounts of linoleic acid gave a similar 
morphology to unmodified cements, low-modulus cements containing much higher 
amounts of ricinoleic acid and castor oil gave a more porous structure. Ricinoleic acid 
appeared to have inherent antibacterial properties.  
 
5. Conclusion 
The addition of fatty acids or triglyceride oils is a simple and effective method to 
modify the properties of existing commercial bone cements or to design new bone 
cements with bone-compliant mechanical properties and antibacterial properties. 
Specifically, very small amounts of linoleic acid (<2.0 wt%) can be used to obtain 
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Young’s moduli and compressive strengths in the range of human trabecular bone. 
Further, the addition of 12.6 wt% ricinoleic acid to Osteopal V cement was found to 
have a significant antibacterial effect, inhibiting growth of Staphylococcus aureus in 
an agar diffusion test as well as demonstrating 100% bactericidal activity against the 
same strain. This suggests that ricinoleic acid could replace commonly used 
antibiotics in some instances, e.g. in pre-polymerized beads; whereas if only a 
reduction in modulus is desired, linoleic acid could be used, e.g. in vertebroplasty. 
 
Acknowledgements 
N/A 
 
Declaration of conflicting interests 
One of the materials evaluated in this study has been described in patent application 
nr PCT/SE2014/050429, where co-authors Cecilia Persson and Alejandro López are 
co-inventors. Co-authors Elise Robert, Elin Carlsson, Maria Godoy-Gallardo, Maria-
Pau Ginebra and Håkan Engqvist have no conflicts of interest. 
 
Funding 
This work was supported by the EU [grant number FP7-PEOPLE-2010-268134], 
VINNOVA [VINNMER project 2010-02073], the Swedish Foundation for 
International Cooperation in Research and Higher Education (STINT) [grant number 
IG2011-2047], and the Spanish Government [Project MAT2012-38438-C03-01, co-
funded by the EU through European Regional Development Funds]. Support for the 
research of MPG was received by the Generalitat de Catalunya [ “ICREA Academia” 
prize for excellence in research]. 
 
References 
 
1. Charnley J. Anchorage of the Femoral Head Prosthesis to the Shaft of the 
Femur. Journal of Bone & Joint Surgery, British Volume. 1960; 42-B: 28-30. 
2. Galibert P, Deramond H, Rosat P, et al. Preliminary note on the treatment of 
vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie. 
1987; 33: 166-168. 
3. O'Brien JP, Sims JTandEvans AJ. Vertebroplasty in Patients with Severe 
Vertebral Compression Fractures: A Technical Report. American Journal of 
Neuroradiology. 2000; 21: 1555-1558. 
	   16	  
4. Magnan B, Bondi M, Maluta T, et al. Acrylic bone cement: current concept 
review. Musculoskelet Surg. 2013; 97: 93-100. 
5. Webb JCJandSpencer RF. The role of polymethylmethacrylate bone cement in 
modern orthopaedic surgery. Journal of Bone & Joint Surgery, British Volume. 
2007; 89-B: 851-857. 
6. Hernández L, Parra J, Vázquez B, et al. Injectable acrylic bone cements for 
vertebroplasty based on a radiopaque hydroxyapatite. Bioactivity and 
biocompatibility. Journal of Biomedical Materials Research Part B: Applied 
Biomaterials. 2009; 88B: 103-114. 
7. Fourney DR, Schomer DF, Nader R, et al. Percutaneous vertebroplasty and 
kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg. 
2003; 98: 21-30. 
8. Lewis G. Injectable bone cements for use in vertebroplasty and kyphoplasty: 
state-of-the-art review. J Biomed Mater Res B Appl Biomater. 2006; 76: 456-
468. 
9. Boger A, Wheeler K, Montali A, et al. NMP-modified PMMA bone cement 
with adapted mechanical and hardening properties for the use in cancellous 
bone augmentation. J Biomed Mater Res B Appl Biomater. 2009; 90: 760-766. 
10. Grados F, Depriester C, Cayrolle G, et al. Long-term observations of vertebral 
osteoporotic fractures treated by percutaneous vertebroplasty. Rheumatology. 
2000; 39: 1410-1414. 
11. Uppin AA, Hirsch JA, Centenera LV, et al. Occurrence of new vertebral body 
fracture after percutaneous vertebroplasty in patients with osteoporosis1. 
Radiology. 2003; 226: 119-124. 
12. Trout AT, Kallmes DFandKaufmann TJ. New Fractures after Vertebroplasty: 
Adjacent Fractures Occur Significantly Sooner. AJNR Am J Neuroradiol. 2006; 
27: 217-223. 
13. Chen W-J, Kao Y-H, Yang S-C, et al. Impact of Cement Leakage Into Disks on 
the Development of Adjacent Vertebral Compression Fractures. Journal of 
Spinal Disorders & Techniques. 2010; 23: 35-39. 
14. Kurtz SM, Villarraga ML, Zhao K, et al. Static and fatigue mechanical behavior 
of bone cement with elevated barium sulfate content for treatment of vertebral 
compression fractures. Biomaterials. 2005; 26: 3699-3712. 
15. Hernandez L, Muñoz ME, Goñi I, et al. New injectable and radiopaque 
antibiotic loaded acrylic bone cements. Journal of Biomedical Materials 
Research Part B: Applied Biomaterials. 2008; 87B: 312-320. 
16. Morgan EF, Bayraktar HHandKeaveny TM. Trabecular bone modulus-density 
relationships depend on anatomic site. J Biomech. 2003; 36: 897-904. 
17. Nazarian A, von Stechow D, Zurakowski D, et al. Bone volume fraction 
explains the variation in strength and stiffness of cancellous bone affected by 
metastatic cancer and osteoporosis. Calcif Tissue Int. 2008; 83: 368-379. 
18. Kopperdahl DLandKeaveny TM. Yield strain behavior of trabecular bone. J 
Biomech. 1998; 31: 601-608. 
19. Burton AW, Mendoza T, Gebhardt R, et al. Vertebral compression fracture 
treatment with vertebroplasty and kyphoplasty: experience in 407 patients with 
1,156 fractures in a tertiary cancer center. Pain Med. 2011; 12: 1750-1757. 
20. Nieuwenhuijse MJ, Putter H, van Erkel AR, et al. New vertebral fractures after 
percutaneous vertebroplasty for painful osteoporotic vertebral compression 
fractures: a clustered analysis and the relevance of intradiskal cement leakage. 
Radiology. 2013; 266: 862-870. 
	   17	  
21. Trout AT, Kallmes DF, Layton KF, et al. Vertebral endplate fractures: an 
indicator of the abnormal forces generated in the spine after vertebroplasty. J 
Bone Miner Res. 2006; 21: 1797-1802. 
22. Berlemann U, Ferguson SJ, Nolte L-P, et al. Adjacent vertebral failure after 
vertebroplasty: a biomechanical investigation. The Journal of Bone & Joint 
Surgery (British Volume). 2002; 84-B: 748-752. 
23. Baroud G, Nemes J, Heini P, et al. Load shift of the intervertebral disc after a 
vertebroplasty: a finite-element study. European Spine Journal. 2003; 12: 421-
426. 
24. Dean JR, Ison KTandGishen P. The strengthening effect of percutaneous 
vertebroplasty. Clin Radiol. 2000; 55: 471-476. 
25. Liebschner MAK, Rosenberg WSandKeaveny TM. Effects of Bone Cement 
Volume and Distribution on Vertebral Stiffness After Vertebroplasty. Spine. 
2001; 26: --. 
26. Reidy D, Ahn H, Mousavi P, et al. A biomechanical analysis of intravertebral 
pressures during vertebroplasty of cadaveric spines with and without simulated 
metastases. Spine. 2003; 28: 1534-1539. 
27. Boger A, Bisig A, Bohner M, et al. Variation of the mechanical properties of 
PMMA to suit osteoporotic cancellous bone. Journal of Biomaterials Science, 
Polymer Edition. 2008; 19: 1125-1142. 
28. Boger A, Bohner M, Heini P, et al. Performance of vertebral cancellous bone 
augmented with compliant PMMA under dynamic loads. Acta Biomaterialia. 
2008; 4: 1688-1693. 
29. Boger A, Wheeler K, Montali A, et al. NMP-modified PMMA bone cement 
with adapted mechanical and hardening properties for the use in cancellous 
bone augmentation. Journal of Biomedical Materials Research Part B: Applied 
Biomaterials. 2009; 90B: 760-766. 
30. Beck SandBoger A. Evaluation of the particle release of porous PMMA 
cements during curing. Acta Biomater. 2009; 5: 2503-2507. 
31. Seniha Güner F, Yagci YandTuncer Erciyes A. Polymers from triglyceride oils. 
Progress in Polymer Science. 2006; 31: 633-670. 
32. Vázquez B, Deb S, Bonfield W, et al. Characterization of new acrylic bone 
cements prepared with oleic acid derivatives. Journal of Biomedical Materials 
Research. 2002; 63: 88-97. 
33. Lam WM, Pan HB, Fong MK, et al. In Vitro characterization of low modulus 
linoleic acid coated strontium-substituted hydroxyapatite containing PMMA 
bone cement. Journal of Biomedical Materials Research Part B: Applied 
Biomaterials. 2011; 96B: 76-83. 
34. Lopez A, Hoess A, Thersleff T, et al. Low-modulus PMMA bone cement 
modified with castor oil. Biomed Mater Eng. 2011; 21: 323-332. 
35. Webb JCandSpencer RF. The role of polymethylmethacrylate bone cement in 
modern orthopaedic surgery. J Bone Joint Surg Br. 2007; 89: 851-857. 
36. Zheng CJ, Yoo JS, Lee TG, et al. Fatty acid synthesis is a target for antibacterial 
activity of unsaturated fatty acids. FEBS Lett. 2005; 579: 5157-5162. 
37. Valera MC, Maekawa LE, Chung A, et al. Effectiveness of castor oil extract on 
Escherichia coli and its endotoxins in root canals. Gen Dent. 2012; 60: e204-
209. 
38. ISO 5833 Implants for surgery - Acrylic resin cements. The International 
Organization for Standardization; 2002. 
	   18	  
39. Baleani M, Persson C, Zolezzi C, et al. Biological and biomechanical effects of 
vancomycin and meropenem in acrylic bone cement. J Arthroplasty. 2008; 23: 
1232-1238. 
40. Bertazzoni Minelli E, Benini A, Samaila E, et al. Antimicrobial activity of 
gentamicin and vancomycin combination in joint fluids after antibiotic-loaded 
cement spacer implantation in two-stage revision surgery. J Chemother. 2014: 
1973947813Y0000000157. 
41. ISO 10993-5: Biological evaluation of medical devices - Part 5: Tests for in 
vitro cytotoxicity.: International Organization for Standardization; 2009. 
42. Guo JandSchork FJ. Hybrid miniemulsion polymerization of acrylate/oil and 
acrylate/fatty acid systems. Macromolecular Reaction Engineering. 2008; 2: 
265-276. 
43. Lam WM, Pan HB, Fong MK, et al. In Vitro characterization of low modulus 
linoleic acid coated strontium-substituted hydroxyapatite containing PMMA 
bone cement. J Biomed Mater Res B Appl Biomater. 2011; 96: 76-83. 
44. Li S, Chien SandBranemark PI. Heat shock-induced necrosis and apoptosis in 
osteoblasts. J Orthop Res. 1999; 17: 891-899. 
45. Berman AT, Reid JS, Yanicko DR, Jr., et al. Thermally induced bone necrosis 
in rabbits. Relation to implant failure in humans. Clin Orthop Relat Res. 1984: 
284-292. 
46. Narasimhan B, Mourya VKandDhake AS. QSAR studies of antibacterial 
ricinoleic acid derivatives. Pharmaceutical Chemistry Journal. 2007; 41: 133-
139. 
47. Gough JEandDownes S. Osteoblast cell death on methacrylate polymers 
involves apoptosis. J Biomed Mater Res. 2001; 57: 497-505. 
48. Geurts JA, Janssen DM, Kessels AG, et al. Good results in postoperative and 
hematogenous deep infections of 89 stable total hip and knee replacements with 
retention of prosthesis and local antibiotics. Acta Orthop. 2013; 84: 509-516. 
 
 
  
	   19	  
Table 1. Mechanical properties (E: Young’s modulus; σ c: compressive strength) of unmodified bone 
cements Simplex P and Osteopal V 
 
 Simplex P (n = 10) Osteopal V (n = 6) 
E [MPa] 1632 ± 39 1524 ± 66 
σ c [MPa] 81.6 ± 2.6 77.0 ± 1.6 
 
 
 
 
 
	   20	  
Table 2. Mechanical properties (E: Young’s modulus; σ c: compressive strength) of fatty acid modified bone cements at different concentrations (wt% of total cement). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 Ricinoleic acid [wt%] 3.35 (n = 6) 6.60 (n = 6) 9.75 (n = 4) 12.80 (n = 6) 15.77 (n = 4) - 
E [MPa] Simplex P 1504 ± 179 1294 ± 39 1143 ± 36 507 ± 149 313 ± 70 - 
σ c [MPa]  63.7 ± 16.6 40.6 ± 1.3 29.4 ± 0.6 12.0 ± 1.0 7.1 ± 0.2 - 
 Ricinoleic acid [wt%] 3.61 (n = 5) 7.10 (n = 8) 10.48 (n = 4) 13.76 (n = 6) - - 
E [MPa] Osteopal V 1393 ± 41.4  1047 ± 64 798 ± 45  424 ± 40  - - 
σ c [MPa]  49.6 ± 2.2  31.8 ± 1.0 21.0 ± 3.7  10.8 ± 1.2  - - 
 Methyl linoleate [wt%] 0.68 (n = 6) 1.02 (n = 6) 1.35 (n = 6) 1.69 (n = 6) 2.02 (n = 6) 2.69 (n = 6) 
E [MPa] Simplex P 1477 ± 209  1367 ± 68  1131 ± 27  947 ± 41  502 ± 27  307 ± 6  
σ c [MPa]  63.6 ± 1.5  49.2 ± 2.0  31.7 ± 0.5  23.1 ± 0.3  12.6 ± 0.2  6.6 ± 0.1  
 Methyl linoleate [wt%] 0.37 (n = 6) 0.55 (n = 5) 0.91 (n = 5) - - - 
E [MPa] Osteopal V 1563 ± 127  1143 ± 66  456 ± 16  - - - 
σ c [MPa]  54.1 ± 1.3  33.8 ± 1.6  9.8 ± 0.3  - - - 
 Linoleic acid [wt%] 0.34 (n = 6) 0.68 (n = 6) 1.02 (n = 6) 1.36 (n = 6) 1.69 (n = 6) 2.02 (n = 6) 
E [MPa] Simplex P 1565 ± 40  1488 ± 52  1190 ± 71  768 ± 19  424 ± 17 249 ± 10 
σ c [MPa]  70.2 ± 2.8 60.3 ± 2.2  61.8 ± 0.9  18.6 ± 0.3  10.5 ± 0.3 5.9 ± 0.2 
 Linoleic acid [wt%] 0.50 (n = 6) 0.75 (n = 6) 1.00 (n = 6) - - - 
E [MPa] Osteopal V 1486 ± 51 1047 ± 61 337 ± 53 - - - 
σ c [MPa]  53.0 ± 1.6 27.2 ± 0.7 11.4 ± 0.9 - - - 
	   21	  
Table 3. Mechanical properties (E: Young’s modulus; σc: compressive strength) of triglyceride oil modified bone cements at different concentrations (wt% of total cement). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Linseed oil [wt%] 3.35 (n = 6) 6.60 (n = 3) 9.75 (n = 6) 10.99 (n = 5) 12.81 (n = 6) - - 
E [MPa] Simplex P 1291 ± 53 1309 ± 35 1103 ± 175 606 ± 91 402 ± 124 - - 
σc [MPa]  46.7 ± 1.4 43.4 ± 2.4 34.6 ± 6.1 16.6 ± 2.4 10.1 ± 2.0 - - 
 Linseed oil [wt%] 0.73 (n = 6) 1.82 (n = 6) 2.36 (n = 5) - - - - 
E [MPa] Osteopal V 705 ± 76 631 ± 36 408 ± 31 - - - - 
σc [MPa]  17.9 ± 2.2 14.7 ± 1.0 10.0 ± 0.4 - - - - 
 Tung oil [wt%] 0.17 (n = 6) 0.31 (n = 6) 0.68 (n = 6) 1.35 (n = 6) - - - 
E [MPa] Simplex P 1460 ± 72 1473 ± 27 1200 ± 30 310 ± 33 - - - 
σc [MPa]  68.7 ± 1.9 61.4 ± 3.9 37.7 ± 0.9 8.1 ± 0.8 - - - 
 Tung oil [wt%] 0.18 (n = 6) 0.37 (n = 6) - - - - - 
E [MPa] Osteopal V 1505 ± 66 16 ± 4 - - - - - 
σc [MPa]  46.6 ± 1.6 0.6 ± 0.1 - - - - - 
 Castor oil [wt%] 3.35 (n = 6) 8.18 (n = 6) 9.74 (n = 5) 11.27 (n = 4) 12.79 (n = 6) 14.57 (n = 6) 16.90 (n = 6) 
E [MPa] Simplex P 1594 ± 36 1352 ± 38 1137 ± 27 861 ± 60 644 ± 51 558 ± 51 217 ± 36 
σc [MPa]  77.9 ± 2.5 46.1 ± 5.1 38.7 ± 1.3 26.8 ± 1.2 16.8 ± 1.1 13.0 ± 1.1 4.1 ± 0.3 
 Castor oil [wt%] 7.78 (n = 6) 10.47 (n = 5) 12.77 (n = 8) 13.73 (n = 5) - - - 
E [MPa] Osteopal V 1190 ± 35 786 ± 87 429 ± 71 361 ± 38 - - - 
σc [MPa]  38.4 ± 1.5 23.8 ± 2.3 12.7 ± 2.3 10.3 ± 1.1 - - - 
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Table 4. Mechanical properties (E: Young’s modulus; σc: compressive strength) of the selected 
cements, with and without Vancomycin. 
 
Without 
Vancomycin OP (n = 6) OP-1.0%LA (n = 8) OP-12.6%RA (n=6) OP-12.3%CO (n=6) 
E [MPa] 1524 ± 66  337 ± 53 418 ± 21 432 ± 59 
σc [MPa] 77.0 ± 1.6 11.4 ± 0.9 15.5 ± 2.6 15.1 ± 4.0 
With 
Vancomycin OP-VA (n = 7) OP-1.0%LA-VA (n = 7) OP-12.6%RA-VA (n=6) OP-12.3%CO-VA (n=6) 
E [MPa] 1653 ± 57 427 ± 37 406 ± 41 417 ± 58 
σc [MPa] 77.9 ± 1.7 12.4 ± 0.4 13.9 ± 1.3 14.5 ± 3.8 
 
 
 
 
 
Table 5. Effect of additives on the setting time, maximum polymerization temperature and glass 
transition temperature of the selected cements.  
Cement 
Setting time 
[min] 
Peak temperature 
[°C] 
Tg (°C) 
OP 21.1 ± 1.1 63.5 ± 2.6 98.4  
OP-1.0%LA 19.7 ± 0.9 35.3 ± 0.4 86.4 
OP-12.6%RA 13.7 ± 0.7 35.0 ± 0.8 57.7 
OP-12.3%CO 15.6 ± 0.1  34.2 ± 2.7 74.0 
 
 
  
	   23	  
 
 
Figure 1. Representative scanning electron micrographs of A) unmodified OP; B) 
OP-1.0%LA; C) OP-12.6%RA; D) OP-12.3%CO.  
 
 
 
 
 
 
 
Figure 2. The resulting inhibitory zone from the agar diffusion test (A) and the % 
viable bacteria after exposure to extracts of the evaluated cements (B). Results are 
presented as average values ± standard deviation, for six replicates per group for the 
results in (A) and 4 replicates per group for the results in (B), except for OP-
12.3%CO, where only 3 data points were available for (B). 
